Xterna
3 known investors
Xterna develops xeno nucleic acid (XNA) technology to engineer cell-specific binders aimed at treating diseases currently considered untreatable. The company operates in the biotechnology and therapeutics space.
Investors · 3
Competitors · 9
by search overlapSepterna6 shared keywordsSepterna develops oral small molecule drug candidates targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex Platform. The company's pipeline focuses on endocrinology, immunology and inflammation, and metabolic diseases for patients with unmet medical needs.
InteRNA5 shared keywordsInterna develops the molecular nano motor (MNM), a technology for delivering large molecules into cells using energy intrinsic to cell membranes. The platform can be adapted to different molecular cargoes and administration methods.
Externa5 shared keywordsExterna develops biologics using genetic code expansion, a technology aimed at incorporating synthetic amino acids into proteins of any type and size. The company positions its platform for partnerships in protein and biologics development.
Therna5 shared keywordsTherna Biosciences designs programmable RNA therapeutics by combining RNA foundation models (its RNA-Logix platform) with proprietary experimental datasets. The company develops medicines for cardiovascular, metabolic, and immunological diseases, including single-patient programs for ultra-rare conditions.
Avernatx4 shared keywordsAverna Therapeutics is a biotechnology company developing therapeutics. The page is a team bio profiling its CEO and board member.
Inspirna4 shared keywordsInspirna is a clinical-stage biopharmaceutical company developing first-in-class cancer therapeutics, including oral small molecules and biologics that target newly discovered drivers of metastasis in common cancers such as colorectal, non-small cell lung, and endometrial cancer. It uses its proprietary RNA-DRIVEr platform and microRNA mapping to identify cancer drivers for patients with high unmet medical needs.
AllTrna4 shared keywordsAlltrna develops engineered, chemically modified tRNA oligonucleotides as programmable medicines, using proprietary machine learning tools to design tRNA molecules with desired pharmacologic properties. Its initial therapeutic focus is treating nonsense mutations by reading through premature termination codons to restore full-length protein production, addressing a category it calls Stop Codon Disease.
Entrada Therapeutics, Inc.3 shared keywordsEntrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells. Its pipeline spans discovery to clinical-stage treatments for retinal, neuromuscular, and metabolic diseases, including Duchenne muscular dystrophy.
bio3 shared keywordsThe Biotechnology Innovation Organization (BIO) is an advocacy organization representing biotech companies, industry leaders, and state biotech associations across the United States and more than 35 countries. It provides members with policy advocacy, cost-saving programs, educational webinars, and organizes the BIO International Convention and other industry conferences.
Companies competing with Xterna for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Xterna do?
- Xterna develops xeno nucleic acid (XNA) technology to engineer cell-specific binders aimed at treating diseases currently considered untreatable. The company operates in the biotechnology and therapeutics space.
- Who are Xterna's investors?
- Xterna's investors include SciFounders, Reinforced Ventures, BoxOne Ventures.